MARKET

XAIR

XAIR

Beyond Air Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.69
+0.23
+4.21%
Closed 16:29 09/18 EDT
OPEN
5.54
PREV CLOSE
5.46
HIGH
5.86
LOW
5.52
VOLUME
171.95K
TURNOVER
--
52 WEEK HIGH
12.50
52 WEEK LOW
3.450
MARKET CAP
97.57M
P/E (TTM)
-3.7563
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Beyond Air to Present at the Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit
GARDEN CITY, N.Y., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary
GlobeNewswire · 09/11 12:00
Beyond Air® to Present Posters on CoronaVirus and Bronchiolitis at the CHEST 2020 Annual Meeting
GARDEN CITY, N.Y., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary
GlobeNewswire · 09/09 13:00
Beyond Air To Present Posters On Coronavirus, Bronchiolitis At CHEST 2020 Annual Meeting
Beyond Air® to Present Posters on CoronaVirus and Bronchiolitis at the CHEST 2020 Annual Meeting GARDEN CITY, N.Y., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a clinical-stage medical device
Benzinga · 09/09 12:06
What Type Of Shareholders Own The Most Number of Beyond Air, Inc. (NASDAQ:XAIR) Shares?
A look at the shareholders of Beyond Air, Inc. (NASDAQ:XAIR) can tell us which group is most powerful. Insiders often...
Simply Wall St. · 08/27 13:59
Beyond Air® to Present New Nitric Oxide Data in an e-Poster Presentation at the North America Conference on Lung Cancer 2020 (NACLC 2020)
GARDEN CITY, N.Y., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary
GlobeNewswire · 08/27 13:00
Beyond Air Announces On August 12, Co. Entered Manufacture And Supply Agreement For Medical Products With Medisize Ireland Limited
Benzinga · 08/18 21:06
Beyond Air® Reports Financial Results for First Quarter of Fiscal Year 2021 and Provides Business Update
U.S. COVID-19 study showing positive safety profile for patients enrolled to date PMA for LungFitTM PH to treat persistent pulmonary hypertension of the newborn (PPHN) expected to be submitted to the FDA at the end of September 2020LungFitTM HOME nontuberculo
GlobeNewswire · 08/06 11:45
Beyond Air Has Huge Long-Term Potential
Seeking Alpha · 07/30 17:06
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average XAIR stock price target is 13.25 with a high estimate of 17.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 55
Institutional Holdings: 3.72M
% Owned: 21.68%
Shares Outstanding: 17.15M
TypeInstitutionsShares
Increased
17
1.16M
New
31
756.41K
Decreased
1
5.44K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.01%
Healthcare Equipment & Supplies
-0.40%
Key Executives
Chairman/Chief Executive Officer/Director
Steven Lisi
President/Chief Operating Officer/Director
Amir Avniel
Chief Financial Officer
Douglas Beck
General Counsel
Adam Newman
Other
Duncan Fatkin
Independent Director
Ron Bentsur
Independent Director
Robert Carey
Independent Director
William Forbes
Director
Lee Yoori
Independent Director
Yoori Lee
Independent Director
Erick Lucera
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average XAIR stock price target is 13.25 with a high estimate of 17.00 and a low estimate of 9.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About XAIR
Beyond Air, Inc., formerly AIT Therapeutics, Inc., is a medical device company. The Company is focused on developing a nitric oxide (NO) generator and delivery system that generates NO from ambient air. The Beyond Air NOGDS is designed to deliver a dosage of NO to the lungs. The Company focuses on areas, such as persistent pulmonary hypertension of the newborn (PPHN), bronchiolitis (BRO) and nontuberculous mycobacteria (NTM). Its Beyond Air NOGDS also delivers a high concentration of NO to the lungs. The Company’s products include Beyond Air- PH, Beyond Air- BRO and Beyond Air- NTM.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Beyond Air Inc stock information, including NASDAQ:XAIR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XAIR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XAIR stock methods without spending real money on the virtual paper trading platform.